CHRM1 and cancer: For example, our analysis of M1R versus M3R expression in progressive colon neoplasia (Figure 1) suggests the potential of using the M3R:M1R expression ratio as a biomarker to predict which cancers are better suited for treatment with M3R inhibitors versus M1R agonists (i.e., M1Rlow vs. M1Rhigh).